Opinion

Video

Emerging Therapies for Dry Eye Disease

Author(s):

William B. Trattler, MD,Crystal Brimer, OD, FAAO

Crystal Brimer, OD, and Kelly K. Nichols, OD, MPH, PhD, discuss two treatments, AZR-MD-001 and Reproxalap, that are in the pipeline to treat patients with dry eye disease (DED).

Related Videos
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Alice Epitropoulos, MD, and Laura M. Periman, MD
Related Content
Study finds increased air pollution leads to surge in daily eye clinic visits
December 9th 2024

Study finds increased air pollution leads to surge in daily eye clinic visits

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Cambium Bio completes funding to help advance dry eye disease treatment
December 5th 2024

Cambium Bio completes funding to help advance dry eye disease treatment

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye
November 19th 2024

FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye

Sun Pharma announces positive Phase 4 data results in dry eye disease
November 14th 2024

Sun Pharma announces positive Phase 4 data results in dry eye disease

© 2024 MJH Life Sciences

All rights reserved.